ArticleMicrobial risk analysis2018
Using thermodynamic parameters to calibrate a mechanistic dose-response for infection of a host by a virus.
Article in Microbial risk analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- From Trait-Structured Within-Host Dynamics to SIR Models: A Multiscale Framework With Re-Exposure.Bulletin of mathematical biology · 2026Article
- Ghosts of the past: Elemental composition, biosynthesis reactions and thermodynamic properties of Zeta P.2, Eta B.1.525, Theta P.3, Kappa B.1.617.1, Iota B.1.526, Lambda C.37 and Mu B.1.621 variants of SARS-CoV-2.Microbial risk analysis · 2023Article
- SARS-CoV-2 strain wars continues: Chemical and thermodynamic characterization of live matter and biosynthesis of Omicron BN.1, CH.1.1 and XBC variants.Microbial risk analysis · 2023Article
- XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2.Microbiological research · 2023Article
- Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.Microbial risk analysis · 2023Article
- Clinical features and transmission risk analysis of dengue virus infections in Shenzhen, During 2014-2019.Computational and structural biotechnology journal · 2023Article
- Review
- Strain wars 5: Gibbs energies of binding of BA.1 through BA.4 variants of SARS-CoV-2.Microbial risk analysis · 2022Article
- Beyond COVID-19: Do biothermodynamic properties allow predicting the future evolution of SARS-CoV-2 variants?Microbial risk analysis · 2022Article
- Why doesn't Ebola virus cause pandemics like SARS-CoV-2?Microbial risk analysis · 2022Article
- Strain wars 3: Differences in infectivity and pathogenicity between Delta and Omicron strains of SARS-CoV-2 can be explained by thermodynamic and kinetic parameters of binding and growth.Microbial risk analysis · 2022Article
- Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding.Biotech (Basel (Switzerland)) · 2022Article
- Using thermodynamic equilibrium models to predict the effect of antiviral agents on infectivity: Theoretical application to SARS-CoV-2 and other viruses.Microbial risk analysis · 2022Article
- Thermodynamic equilibrium dose-response models for MERS-CoV infection reveal a potential protective role of human lung mucus but not for SARS-CoV-2.Microbial risk analysis · 2020Article
- How virus size and attachment parameters affect the temperature sensitivity of virus binding to host cells: Predictions of a thermodynamic model for arboviruses and HIV.Microbial risk analysis · 2020Article
- Dose-response and transmission: the nexus between reservoir hosts, environment and recipient hosts.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- Towards a thermodynamic mechanistic model for the effect of temperature on arthropod vector competence for transmission of arboviruses.Microbial risk analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessing the risk of infection from emerging viruses or of existing viruses jumping the species barrier into novel hosts is limited by the lack of dose response data. The initial stages of the infection of a host by a virus involve a series of specific contact interactions between molecules in the host and on the virus surface. The strength of the interaction is quantified in the literature by the dissociation constant (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.